Idenix Pharma Q2 revenues down

Idenix Pharma’s net loss was $13.91m, or $0.15 loss per diluted share, compared to net loss of $16.26m, or $0.23 loss per diluted share, for the same period in 2010.

The company’s loss from operations for the second quarter of 2011 was $14.28m, compared to operating loss of $16.6m for the same period in 2010.

For the six months ended 30 June 2011, the company reported total revenues of $5.05m, compared to $4m for the same period in 2010.

The company has reported net loss of $22.15m or 0.27 loss per diluted share for the six months ended 30 June 2011, as compared to $32.47m or $0.47 loss per diluted share for the same period in 2010.

Idenix Pharma’s loss from operations were $22.82m for the six months of 2011, compared to $33.25m for the same period in 2010.